The public announcement of the success of immunotherapy medication in treating cancer appears to be a major step forward. But will it really offer a cure for patients? Work on this range of therapy has been carrying on for some time - and companies were seeking investment in this area at the recent Biotrininty conference. Whilst the trial results certainly look spectacular the problem will be the price of the drugs and whether they receive NICE approval. In the last couple of days it was announced that NICE has turned down Olaparib as a treatment for ovarian cancer with its annual price tag of over £49k. The price of drugs has long been a subject of debate, which was added to by Dr Leonard Saltz at the annual meeting of the American Society of Clinical Oncology at the weekend when he cited statistics showing an doubling of the median monthly price fro new cancer drugs in the period 2000/2004 to 2010/14.